NeuroSense Therapeutics Publicly Files Registration Statement with SEC for Proposed U.S. Initial Public Offering

Cambridge, Mass.: Cambridge, Mass., Oct. 19, 2021 /PRNewswire/ — NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, announced today that it has publicly filed an F-1 Registration Statement (File No.: 333-260338) with the U.S. Securities and Exchange Commission relating to a proposed U.S. initial public offering. The number of securities to be offered and the price range for the proposed offering have not yet been determined. NeuroSense has applied to list its ordinary shares on the Nasdaq Capital Market under the symbol "NRSN" and has applied to list the warrants to be issued in the offering under the symbol "NRSNW".
Click here to view original post